Report

ABC arbitrage - Equity markets remain calm

ABC arbitrage group (ABCA) reported net income of €8.8m in H123, down 46% y-o-y, which in our view represents a reasonable result amid unfavourable market conditions. The market continues to be characterised by low volatility and limited M&A activity, weighing on ABCA’s main arbitrage strategies. After the end of June 2023, both ABCA Opportunities and ABCA Reversion funds managed to show strong performance, improving the outlook for the H223 results. Meanwhile, ABCA’s AUM remained flat in H123. The company reiterated its intention to pay out 80% of profits in dividends, with a minimum DPS of €0.30.
Underlying
ABC arbitrage SA

ABC Arbitrage is an investment consulting company and financial services provider that designs arbitrage strategies on European & U.S. financial markets. Co. provides holding company services, such as, communication, legal, labor relations & human resources management, & administrative. It also helps develop third-party asset management services. Co. conducts two types of arbitrage strategies: Arbitrages without market risks (Self-liquidating arbitrage strategies) and Arbitrages with market risks (Suspensive clause arbitrage strategies). In Arbitrages with market risks, the legally binding documentation governing suspensive clause arbitrage strategies does not guarantee convergence.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Pedro Fonseca

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch